add_event_1.jpg


events_sidebar_calendar_header.gif

Photos_with_Santa_teaser.jpg

what_hap_signup_300x45.jpg

community_header.jpg
BG14_sidebar_96x96.jpgBOA14_sidebar_96x96.jpgVG14_sidebar_96x96.jpgobits_96x96.jpgAM14_sidebar_96x96.jpgannounce_96x96.jpg
soa13_300x45.jpg

MoralHazard_eyetear_teasebanner.jpg
shuffler_teaser_300x60.jpg

 

 

 

 

 

 

 
Home / Articles / News / Campus NEWS /  University has new board member
. . . . . . .
Sunday, September 30,2012

University has new board member

Ohio Gov. John Kasich has named an Athens-based executive in the health-care industry as the newest member of Ohio University's Board of Trustees.

On Friday, Kasich announced the appointment of David R. Scholl to the board. Scholl will serve a nine-year term, running through May 2021.

Scholl, who has lived in Athens 35 years, is a partner with Athenian Venture Partners in its health-care practice. Before AVP, Scholl was senior vice president of Diagnostic Hybrids, Inc., a biotechnology diagnostic firm he helped establish with fellow OU alumni in 1983.

A market leader in the development and distribution of cellular and molecular diagnostic kits, DHI was purchased by Quidel Corporation in 2010 for over $130 million, with Scholl serving as senior vice president. He retired from the company in 2011.

In a prepared release, OU President Roderick McDavis said he was "very pleased" to welcome Scholl to the board.

"An alumnus, he is an outstanding example of the promise of Ohio University," McDavis is quoted as saying. "We look forward to his leadership on our board and the unique perspective he will bring, especially as we focus on enriching the student experience and elevating our leadership role and efforts in the areas of technology transfer and commercialization with the state and nation."

As DHI's CEO since 1997, Scholl built the firm's manufacturing, sales and business development infrastructure, developed long-term relationships with the company's stakeholders, and raised $12.5 million in equity growth capital from Summit Partners to accelerate the company's growth.

He has worked on a wide range of health-care investment opportunities including biopharmaceuticals, gene delivery technology, genomics, bio-imaging technology tissue engineering and cancer therapeutics. Combined with his experience at DHI, Scholl has more than 28 years of health-care experience in venture capital, research and development, and operating management.

"I am genuinely honored and humbled to be considered for this trustee position," Scholl said in the release. "Ohio University has strongly influenced my life, my professional career and my family in so many positive and significant ways. The opportunity to serve this exceptional University in this capacity is very special."

 

  • Currently 3.5/5 Stars.
  • 1
  • 2
  • 3
  • 4
  • 5
 

 
 
Close
Close
Close